872679-70-4 Usage
Description
Fmoc-9-Amino-4,7-Dioxanonanoic acid, also known as Fmoc-AEEP-OH, is a chemical compound that consists of a PEG linker with an Fmoc-protected amine and a terminal carboxylic acid. The hydrophilic PEG spacer enhances solubility in aqueous media, while the Fmoc group can be deprotected under basic conditions to reveal the free amine for further conjugations. The terminal carboxylic acid is capable of reacting with primary amine groups in the presence of activators, such as EDC or HATU, to form stable amide bonds. This white crystalline powder is a valuable component in the synthesis of various bioconjugates and pharmaceutical agents.
Uses
Used in Pharmaceutical Industry:
Fmoc-9-Amino-4,7-Dioxanonanoic acid is used as a building block for the synthesis of glucose-responsive insulin conjugates. This application is crucial for the development of advanced drug delivery systems that can release insulin in response to glucose levels, providing a more effective and targeted treatment for diabetes.
Additionally, due to its ability to form stable amide bonds and its solubility-enhancing PEG spacer, Fmoc-9-Amino-4,7-Dioxanonanoic acid can be utilized in various other applications within the pharmaceutical industry, such as the creation of drug conjugates, prodrugs, and other bioactive molecules. Its versatility in forming stable bonds and improving solubility makes it a valuable asset in the development of innovative therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 872679-70-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,6,7 and 9 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 872679-70:
(8*8)+(7*7)+(6*2)+(5*6)+(4*7)+(3*9)+(2*7)+(1*0)=224
224 % 10 = 4
So 872679-70-4 is a valid CAS Registry Number.
872679-70-4Relevant articles and documents
Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes
Storer, R. Ian,Pike, Andy,Swain, Nigel A.,Alexandrou, Aristos J.,Bechle, Bruce M.,Blakemore, David C.,Brown, Alan D.,Castle, Neil A.,Corbett, Matthew S.,Flanagan, Neil J.,Fengas, David,Johnson, M. Scott,Jones, Lyn H.,Marron, Brian E.,Payne, C. Elizabeth,Printzenhoff, David,Rawson, David J.,Rose, Colin R.,Ryckmans, Thomas,Sun, Jianmin,Theile, Jonathan W.,Torella, Rubben,Tseng, Elaine,Warmus, Joseph S.
, p. 4805 - 4811 (2017)
The discovery and selection of a highly potent and selective NaV1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficacy model data are discussed. A proposed protein–ligand binding mode for this compound is also provided to rationalise the high levels of potency and selectivity over inhibition of related sodium channels. To further support the proposed binding mode, potent conjugates are described which illustrate the potential for development of chemical probes to enable further target evaluation.